Trial Clinico Randomizzato e Doppio-cieco Sull'Efficacia di Una Formulazione Alimentare Contenente Trigliceridi a Media Catena (MCT) e Fibre in Pazienti Con Artrite Psoriasica

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The primary objective of this study is to evaluate the effects of a formulation containing medium-chain triglycerides (MCTs) and vegetable fibers on the quality of life of patients with psoriatic arthritis, by monitoring the patients over a period of 3 months in a single-center interventional study. As secondary objectives, the study will assess the effects of the same formulation on disease activity and on certain blood parameters and dietary habits.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Adult patients: aged 18-80 years;

• Clinical diagnosis of PsA meeting the CASPAR classification criteria;

• Low disease activity (4 \< DAPSA ≤ 14) at the time of recruitment;

• Under stable pharmacological treatment with disease-modifying antirheumatic drugs (DMARDs) (conventional synthetic, targeted synthetic, or biological);

• Disease duration \> 6 months;

• Absence of metabolic diseases.

Locations
Other Locations
Italy
ASST Gaetano Pini CTO, UOC Clinica Reumatologica
RECRUITING
Milan
Contact Information
Primary
Giulia Gaudioso, Medical Affairs Manager, PhD
giulia.gaudioso@drschaer.com
+39 0473 293 642
Backup
Patrizia Zanon, Global R&I Specialist
patrizia.zanon@drschaer.com
+39 342 7452 056
Time Frame
Start Date: 2025-05-16
Estimated Completion Date: 2025-12
Participants
Target number of participants: 60
Treatments
Placebo_comparator: Control placebo group
Patients assigned to this group will consume a placebo powder.
Experimental: MCTs and fiber group (Test group)
Patients assigned to this group will consume twice per day a portion of MCTs and fiber.
Related Therapeutic Areas
Sponsors
Leads: Dr. Schär AG / SPA
Collaborators: ASST Gaetano Pini-CTO

This content was sourced from clinicaltrials.gov